SecBot SecBot

BLRX

BioLineRx Ltd.
Nasdaq· Pharmaceutical Preparations· Inc. L3· CIK 0001498403 Biotech & Drug Discovery
$2.03 +0.02 (+1.00%)
Oct 27 4:00 PM ET · prev $2.01
Market cap
$10.2M
Nano cap
Median target
$22.00
+984% · range $18.00–26.00
1 year
−44.8%
from $3.68 · Oct 28
30 days
−16.5%
from $2.43
52-week range
$1.98–3.78
−46% from high · low Oct 19
Avg volume 20D
15.6K
Sep 30 spike 40.8K
Short interest
136.9K
≈2.8% of shares · −5.9%
Days to cover
8.0
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Reddit crowd
60°
Warm · 1 mention this week
Filing reports
14
analyzed by SecBot
SecBot read BEARISH 9 reports · 90 days
Balance 6 bearish · 1 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 6/9
Strongest BULLISH BioLineRx and Hemispherian presented preclinical data at ESMO 2026 showing GLIX1 synergizes with multiple…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsBEARISH

    Q2 2026: 0 added (0 new), 3 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.180 → −$0.770 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −5.9% to 136.9K shares. 8.0 days to cover, ≈2.8% of shares.

  • TrendDOWNTREND

    17% below its 50-day average.

  • SocialQUIET

    Crowd 60° (warm) this week from 1 mention: 1 bullish, 0 bearish. No setup call.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BNP PARIBAS FINANCIAL MARKETSTRIM500$1.6K
UBS Group AGNEAR_EXIT101$315.00
CITIGROUP INCNEAR_EXIT1$3.00
RHUMBLINE ADVISERSTRIM2,353$5.4K
UBS Group AGTRIM529$1.2K
UBS Group AGTRIM1,951$5.4K
MORGAN STANLEYNEAR_EXIT100$277.00
OSAIC HOLDINGS, INC.DOUBLED26$71.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jun 2025
12-month targets · 2 analysts

Price is below the lowest target. Median implies +984%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Jun 17, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
May 30, 2025Jones Trading
UPGRADE
UPGRADEBuy
May 28, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Apr 2, 2025Jones Trading
DOWNGRADE
DOWNGRADEHold
Mar 31, 2025HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Nov 25, 2024HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Earnings setup

Estimates
−$0.77
EPS estimate, this quarter
−328%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.77-$0.77–-$0.77+0.0%$357.5K
Next Q-$0.80-$0.80–-$0.80+0.0%$492.5K
Current FY-$3.14-$3.14–-$3.14+0.0%$1.6M
Next FY-$2.52-$2.52–-$2.52+0.0%$2.2M
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 23, 2026 SEC
BioLineRx and Hemispherian presented preclinical data at ESMO 2026 showing GLIX1 synergizes with multiple PARP…
6-K — Impact 5/10
Oct 5, 2026 SEC
The SEC declared BioLineRx's F-1 registration statement effective on October 2, 2026, enabling the resale of up to…
EFFECT — Impact 6/10
Sep 25, 2026 SEC
BioLineRx filed an F-1 registration statement to register 2,023,382 ADSs for resale by Armistice Capital, the sole…
F-1 — Impact 4/10
Sep 10, 2026 Other
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
TEL AVIV, Israel and OSLO, Norway, Sept. 10, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TAS
Aug 28, 2026 Press
BioLineRx announced a $3.75M registered direct offering and concurrent private placement, selling 1,348,921 ADSs at…
Impact 6/10
Jun 30, 2026 Inst.
BNP PARIBAS FINANCIAL MARKETS — TRIM
500 shares ($1.6K)
Jun 30, 2026 Inst.
UBS Group AG — NEAR_EXIT
101 shares ($315.00)

Short side

FINRA· Oct 15, 2026
136,917
shares short
-5.9%
vs prior settlement
8.0
days to cover
≈2.8%
of shares outstanding
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 10, 2026
Press release
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
TEL AVIV, Israel and OSLO, Norway, Sept. 10, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical…
Aug 28, 2026
Offering
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement
TEL AVIV, Israel, Aug. 28, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage…
Jul 20, 2026
Press release
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
TEL AVIV, Israel and OSLO, Norway, July 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical…
Mar 13, 2026
Clinical Trial
Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer
Phase 3 · TERMINATED
Reddit
Crowd this week 60° Warm 1 bullish · 0 bearish
Mentions, 7 days 1 1 in posts · 0 in comments
Recent posts
r/pennystocks Bullish 4d ago
$BLRX - BioLineRx and Hemispherian Report GLIX1–PARP Inhibitor Synergy in HR-Proficient Ovarian Cancer
1 upvotes · 1 comments
All social signals and their track records

SecBot reports

14 filings · 1 press release · 5 bullish · 5 bearish · 2 mixed · 2 neutral
All BLRX filing & press-release reports (15)